FGF21 and fatty liver disease: In vivo, SN-401 normalizes glucose tolerance by increasing insulin sensitivity and secretion in insulin-resistant T2D mouse models, while augmenting tissue glucose uptake, suppressing hepatic glucose production, inducing serum FGF21 levels, and reducing hepatic steatosis and hepatocyte damage (ballooning) in obese T2D mice.